Podcasts about fasn

With the launch of a new journal, the American Diabetes Association (ADA) is also launching a brand new podcast: The Points of CARE, the official podcast of Diabetes, Obesity, and CardioMetabolic CARE. Join hosts Richard Beaser, MD and Jane Reusch, MD, as they highlight key research findings, clinical implications, and emerging themes across diabetes, obesity, and cardiometabolic health through interviews with journal authors and subject-matter experts. 1:15 Our hosts speak with Katherine R. Tuttle, MD, FASN, FACP, FNKF, Executive Director of Research at Providence Inland Northwest Health and a Professor of Medicine at the University of Washington School of Medicine. She is an author of the article "SGLT2 Inhibitors for the Primary Prevention of CKD in Type 2 Diabetes: A Systematic Review and Meta-analysis," available at doi.org/10.2337/doci26-0001. 8:50 Next, Richard introduces Alexander Turchin, MD, MS, Director of Informatics Research at the Division of Endocrinology at Brigham and Women's Hospital and Associate Professor of Medicine at Harvard Medical School. He is an author of "Trends in Diabetes Medications After Metformin in Patients at High Versus Moderate Cardiovascular Risk: The BESTMED Consortium 2014–2022," available for free at doi.org/10.2337/doc26-0027. 17:05 Richard and Jane highlight special material available in the latest issue of Diabetes, Obesity, and CardioMetabolic CARE. "Screening, Diagnosis, Evaluation, and Staging of Obesity in Adults: Standards of Care in Overweight and Obesity—2026," available for free at doi.org/10.2337/doci26-0003 "Employment and Diabetes: A Statement of the American Diabetes Association," available for free at doi.org/10.2337/doc25-0092. 23:40 Finally, Richard and Jane highlight some of their favorite articles from the July-August issue. Vidovic, et al. Behavior Modifications From CUT-DM, Including Lifestyle Modification and Self-Efficacy doi.org/10.2337/doc25-0093 Chan, et al. Pharmacist-Driven Pre-Visit Planning to Optimize Prescribing in Type 2 Diabetes doi.org/10.2337/doc26-0019 Bannuru, et al. RAAS Inhibitors for the Primary Prevention of CKD in Type 1 and Type 2 Diabetes: A Systematic Review and Meta-analysis doi.org/10.2337/doci25-0014 Dimentstein, et al. Goals of Care Among Caregivers of Youths With Type 1 Diabetes doi.org/10.2337/doc26-0035 To learn more about Diabetes, Obesity, and CardioMetabolic CARE please visit diabetesjournals.org/docm-care. Thank you for listening, and don't forget to subscribe.

Our kidneys do an incredible job filtering our blood every hour of every day. Most of us have two kidneys, and each one has about a million microscopic filters called glomeruli. Unlike the filters in our HVAC system, though, these filters cannot be replaced. But they do their work so well and unobtrusively that most of us don't even think about our kidney function. Although 37 million Americans have kidney trouble, the majority are unaware of their situation. Two tests could reveal how well the kidneys are working. What are they, and how often should you ask about them? At The People's Pharmacy, we strive to bring you up‑to‑date, rigorously researched insights and conversations about health, medicine, wellness and health policies and health systems. While these conversations intend to offer insight and perspective, the content is provided solely for informational and educational purposes. Please consult your healthcare provider before making any changes to your medical care or treatment. How You Can Listen You could listen through your local public radio station or get the live stream at 7 am EST on Saturday, August 8, 2026, through your computer or smart phone (wunc.org). Here is a link so you can find which stations carry our broadcast. If you can't listen to the broadcast, you may wish to hear the podcast later. You can subscribe through your favorite podcast provider, download the mp3 using the link at the bottom of the page, or listen to the stream on this post starting on August 10, 2026. What Are the Two Tests That Reveal Kidney Trouble? Chronic conditions like high blood pressure and diabetes put a strain on the kidneys. They are very common problems that signal the need for kidney function monitoring. Our guest expert, Dr. Samir Parikh, suggests that all of us should know our numbers. One is derived from the level of creatinine in the blood. This is normally part of a basic metabolic panel. Usually, the panel results will include a number for the estimated glomerular filtration rate (EGFR) calculated from the value for blood creatinine. The other crucial test is a urine test for protein. Keeping Kidneys Healthy by Staying Properly Hydrated One of the simplest tactics to keep kidneys healthy is to provide them with enough liquid. We get some fluid from the food we eat, which may be one reason eating fruits and vegetables seems to be good for us. They are full of water! We also need to drink fluid, and plain water is probably the best choice. It would be smart to use thirst as a guideline and make sure to drink when thirsty. We do avoid overdoing water consumption, though, as overloading the kidneys with more fluid than they can handle is dangerous as well. Medicines That Are Hard on the Kidneys We mentioned to Dr. Parikh the experience of an older friend, a devoted runner, who discovered that taking ibuprofen after a run reduced the likelihood of having to get up overnight to urinate. He reminded us and our listeners that nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, naproxen, celecoxib or meloxicam can be hard on the kidneys. That doesn't mean we shouldn't ever take such pain relievers, but perhaps we should try not to make it a habit. When we asked about other medicines that might be tough on the kidneys, he mentioned PPIs. Proton pump inhibitors such as omeprazole (Prilosec) or esomeprazole (Nexium) are often used to treat heartburn or other digestive symptoms. Regular use can put a strain on the kidneys, although the gastroenterologist recommending the medicine might not warn you of that side effect. We asked about environmental toxins and learned that heavy metals such as lead or arsenic can harm the kidneys along with other organs. We should make sure that the food we eat and the water we drink are not contaminated with such compounds. The Possible Benefits of Vitamin B Dr. Parikh has been studying how the kidneys respond to the B vitamin nicotinamide. The preliminary work he and his colleagues have done so far is promising. However, they have not conducted clinical trials to find out whether the vitamin could help people with early kidney disease. Because kidneys work so hard, they need a lot of energy to be produced by the mitochondria in their cells. Those mitochondria need NAD+ (nicotinamide adenine dinucleotide) to function at their best. Providing additional nicotinamide appears to help (Nature Reviews. Nephrology, Feb. 2020).  One to three grams a day appears to be safe and may be beneficial. Medications That Can Promote Kidney Health Some medicines initially developed for other conditions are proving to be helpful in treating kidney disease. In particular, these include diabetes drugs known as SGLT2 inhibitors like dapagliflozin (Farxiga) or empagliflozin (Jardiance). They help slow the decline of kidney function (New England Journal of Medicine, Nov. 4, 2022). GLP-1 agonists may also be familiar because they too are used to treat diabetes. Medications such as semaglutide (Ozempic, Rybelsus, Wegovy) and tirzepatide (Mounjaro, Zepbound) have made headlines as weight loss and diabetes meds, but they also can reduce the risk of kidney failure and other bad outcomes (Lancet. Diabetes & Endocrinology, Jan. 2025). The benefits of these types of drugs should give us hope that we can go from slowing the progression of kidney disease to stopping it in its tracks Taking Care of Your Kidneys We asked Dr. Parikh what we should be doing to care for our kidneys and keep them healthy. He urged us once again to know our numbers: most importantly, the numbers from the two tests we discussed, blood creatinine and urine protein. Other numbers that are important for kidney are our blood pressure and, for those with diabetes, HbA1c. In addition to paying attention to all those numbers, we need to embrace a lifestyle that will help keep them where they belong. That means following a heart-healthy diet, staying physically active and getting adequate sleep. This Week’s Guest Samir M. Parikh, M.D., FASN, is Professor of Internal Medicine and Pharmacology and Chair of Internal Medicine at the University of Texas Southwestern. He holds the Donald W. Seldin Distinguished Chair in Internal Medicine and the Ruth W. and Milton P. Levy, Sr., Chair in Molecular Nephrology. Dr. Samir Parikh, University of Texas Southwestern Listen to the Podcast The podcast of this program will be available Monday, August 10, 2026, after broadcast on Aug. 8. This week's podcast has additional information on a possible role for sodium bicarbonate (baking soda) for kidney function. We also discussed medical silos, and how that leads to gastroenterologists overlooking the kidney risks from PPIs. Also, what should prospective kidney donors consider? You can stream the show from this site and download the podcast for free. Download the mp3, or listen to the podcast on Apple Podcasts or Spotify.

Listen in as our expert panel untangles the latest recommendations for using equations to estimate kidney function. You'll hear their insights on when and how to use creatinine, cystatin C, or both to help safely adjust medication doses in kidney disease.Special guests:Erin F. Barreto, PharmD, PhD, FCCM, FASN, BCCCPAssociate Professor of Medicine and PharmacyMayo ClinicTracy Anderson-Haag, PharmD, BCPS, BCTXPClinical Pharmacy Specialist-TransplantationResidency Program Director, PGY-2 Solid Organ TransplantHennepin HealthcareNone of the speakers have anything to disclose. This podcast is an excerpt from one of TRC's monthly live CE webinars, the full webinar originally aired in June 2026.

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

John Friedewald, MD, FASN, FAST - Breakthroughs and Buzz From Boston: Key Takeaways for the Kidney Transplant Community

Martina McGrath, MBChB, FASN; Jean Francis, MD, FASN; Ihab Michel Wahba, MD, FASN; and Amir Kazory, MD, FASN, speak with guest editor Biff F. Palmer, MD, to discuss his editorial on Hypernatremia from nephSAP Volume 25, Number 1. 

Martina McGrath, MBChB, FASN; Jean Francis, MD, FASN; Ihab Michel Wahba, MD, FASN; and Amir Kazory, MD, FASN, speak with guest editor Biff F. Palmer, MD, to discuss his editorial on Hypernatremia from nephSAP Volume 25, Number 1. 

Come on the adventure with Drs. Ray Bignall and Lauren Phinney as we discuss the highlights from the first day of the AIMW26 Conference, the Opening Plenary, and the mesmerizing educational sessions. Website | Instagram | Twitter | Subscribe | Patreon | Youtube thecurbsidersteach@gmail.comCredits Producer, Writer, Graphics: Mike KW Cheng MD, MAEd  Hosts: Era Kryzhanovskaya MD, Mike KW Cheng MD, MAEd  Editors:  Era Kryzhanovskaya MD, Mike KW Cheng MD, MAEd, and Molly Heublein MD Reviewer: Era Kryzhanovskaya MD Guests:  O. N. Ray Bignall II, MD, FAAP, FASN and Lauren Phinney, MD Technical support: Podpaste Theme Music: MorsyMusic  Show Segments Intro, disclaimer, guest bio Guest one-liner Experience at AIMW26 thus far The five lessons of mentorship Mentorship is a network The importance of sharing and reflecting on mentee stories Different avenues to set up mentor relationships Bridging the generational gap in academic medicine Best practices for generative AI and LLMS The hidden tax of volunteerism in medical education

In this episode, Vineet Gupta, PhD, FASN, Vice President of the Office of Innovation and Commercialization and CEO of Medical Branch Innovations at The University of Texas Medical Branch, discusses embedding innovation as a fourth pillar alongside clinical care, research, and education. He shares how strategic focus areas such as brain health, kidney health, healthy aging, and AI driven solutions are advancing commercialization, public private partnerships, and systemwide transformation.

Bei strahlendem Wetter zog am Mittwoch der zweite Teil des Cortèges durch die Basler Innenstadt. Tausende aktive und passive Fasnächtlerinnen und Fasnächtler begleiteten das farbenfrohe Treiben. Davor präsentierten auf dem Münsterplatz die Cliquen ihre Lartenen. Ausserdem: · Die Sujets der Stammvereine · Fasnachtsgast: Philippe Gerber, Moderator SRF Querschnitt

Der "ARI-Keller" muss während der Fasnacht geschlossen bleiben. Wir fragen: Wie kommt das bei den Fasnächtlern an?

Strengere Brandschutzregeln sorgen dafür, dass einzelne Basler Cliquenkeller geschlossen bleiben – darunter auch der traditionsreiche ARI-Keller. Während der Wirt auf Einnahmen verzichten muss, weichen die Fasnächtler aus. Das neue Konzept kommt unterschiedlich an. Weitere Themen BE Die Galenica-Tochter Bichsel will ihre pharmazeutische Produktion aus wirtschaftlichen Gründen bis spätestens Ende 2026 aufgeben. 170 Stellen würden gestrichen. Die Auswirkungen auf die Versorgungssicherheit sei gross, heisst es vom Chef-Apotheker der Spitäler in der Region. ZH Präklinische Fachspezialisten rücken aus, wenn es nicht um lebensbedrohliche Notfälle geht. Während Region 144 einen solchen Testversuch eingestellt hat, macht Schutz und Rettung Zürich weiter mit demselben Konzept. GR Die Metzgerei der Justizvollzugsanstalt Realta in Cazis öffnet wieder. Vor gut eineinhalb Jahren hatte sie wegen falsch deklariertem Fleisch für Schlagzeilen gesorgt.

Zehntausende aktive und passive Fasnächtlerinnen und Fasnächtler haben nach dem Morgenstraich den ersten Cortège erlebt. Geprägt war der Nachmittag von den verschiedenen Sujets - von Trump bis Birsfelden. Ausserdem: · Alte Richtig und Schnuurebegge feiern 100-Jahr-Jubiläum · Eine Auswahl Zeedel · Fasnachtsgast: Linda Atz

Legislation has played a defining role in how dialysis care is delivered in the United States, directly influencing access, coverage, and patient choice. In this episode of Kidney Commute: Pitstop, host Osama El Shamy, MD, FASN, FNKF, is joined by Lauren Drew, JD, and Eugene Lin, MD, MS, FASN for an in depth discussion on the policy decisions that have shaped kidney care. The conversation traces key legislative milestones, including the creation of the ESRD benefit, the Medicare dialysis bundle, Medicare Advantage expansion, and the Advancing American Kidney Health Initiative. Speakers also examine the current legislative landscape, its impact on dialysis patient choice, and opportunities for professional advocacy in kidney care.

Alice Sheridan, MD, FASN, Jean Francis, MD, FASN, and Martina McGrath, MBChB, FASN, interview editors Klement Yeung, MD, and Christopher T. Chan, MD on nephSAP editorial "It's Time for Home Hemodialysis to be Treated as an Established Dialysis Modality."

Alice Sheridan, MD, FASN, Jean Francis, MD, FASN, and Martina McGrath, MBChB, FASN, interview editors Klement Yeung, MD, and Christopher T. Chan, MD on nephSAP editorial "It's Time for Home Hemodialysis to be Treated as an Established Dialysis Modality."

Anlässlich der Museumsnacht Basel diskutiert SRF-Mundartredaktor Markus Gasser auf dem Münsterplatz live vor Publikum mit seinen zwei Gästen Flo Baeriswyl und Felix Rudolf von Rohr über Baseldeutsch. Die Kernfrage dabei: Wem gehört Baseldeutsch überhaupt? Man kann in Basel fragen, wen man will: Praktisch niemand wagt zu sagen, er oder sie spreche astreines Baseldeutsch. Die Vorstellung eines «korrekten» Stadtdialekts ist durch die Fasnacht, durch aktive Sprachpfleger und durch das zur Norm gewordene Baseldeutsch-Wörterbuch von Rudolf Suter aus dem Jahr 1984 so stark in den Köpfen verankert, dass die eigene Sprache immer davon abweicht. Wer sagt noch «allewyyl», «Zmoorge dringge» oder «Schungge»? Eben. Aber stimmt diese Beobachtung auch für die junge Generation? Oder hat diese ein ganz anderes Verhältnis zum Baseldeutsch? Wem «gehört» dieser Dialekt eigentlich? Wir reden darüber mit der jungen Autor*in und Journalist*in Flo Baeriswyl und dem Fasnächtler und Berufsbasler Felix Rudolf von Rohr - und wir beziehen Stimmen aus dem Publikum mit ein. Familiennamen Inauen, Indermaur, Inderwildi Alle drei Namen sind sogenannte präpositionale Wohnstättennamen: Zur lokalisierenden Präposition «in» kommt jeweils eine Ortsbezeichnung als Ergänzung. «Au» bedeutet 'Land am Wasser'); «Muur» oder «Mauer» benennt seinen ersten Namensträger wohl als Bewohner eines ummauerten Siedlungs- und Pflanzplatzes; «Wildi» bezeichnet im alpinen Gebiet der Schweiz in der Regel abgelegene, unkultivierte und raue Gebiete oberhalb oder am Rand von Siedlungen, die als Weideland und zur Gewinnung von Wildheu genutzt werden.

Please visit answersincme.com/VTG860 to participate, download slides and supporting materials, complete the post test, and get a certificate. In this activity, an expert in lupus nephritis (LN) discusses the latest evidence and guidance on using biologic therapies in this patient population. Upon completion of this activity, participants should be better able to: Discuss the rationale for adding a biologic agent to standard immunosuppressive therapy to improve outcomes in LN; Review the clinical evidence for available and emerging B-cell biologic agents in LN; and Identify patients with LN who are candidates to receive biologic add-on therapy.

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

Carla M. Nester, MD, MSA, FASN - 2025 Congress Highlights From Houston, Texas: Translating C3G and IC-MPGN Trials to Treatment in an Era of Complement Inhibition

In this Kidney Commute: Pitstop episode, host Anna Gaddy, MD, FASN, FNKF, is joined by Kaice LaFavers, PhD, and Pranav Garimella, MBBS, MPH, to explore uromodulin. They discuss its role in infection defense, immune modulation, AKI and sepsis, genetic insights, and evolving methods to study its multiple forms. A concise, science driven look at why uromodulin matters in kidney health.

Cyrus Khambatta, Ph.D., Sean Hashmi, M.D., MS, FASN, and Robby Barbaro, MPH, provide evidence-based diet and lifestyle strategies proven to prevent diabetes and chronic kidney disease. Learn actionable steps to transform your health through nutrition. #DiabetesPrevention #KidneyHealth #DietaryStrategies

Host Andrew Cohen, MD, discusses the advent of recombinant erythropoietin (rEPO) and its impact on kidney care with Paul Kimmel, MD, FASN; Daniel Coyne, MD; and Ajay Singh, MD. 

Host Andrew Cohen, MD, discusses the advent of recombinant erythropoietin (rEPO) and its impact on kidney care with Paul Kimmel, MD, FASN; Daniel Coyne, MD; and Ajay Singh, MD. 

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Sankar D. Navaneethan, MD, MS, MPH, and Garabed Eknoyan, MD, to discuss their editorial "ESKD: A Therapeutic Triumph of Nephrology" from nephSAP Volume 24, Number 4, ESKD.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Sankar D. Navaneethan, MD, MS, MPH, and Garabed Eknoyan, MD, to discuss their editorial "ESKD: A Therapeutic Triumph of Nephrology" from nephSAP Volume 24, Number 4, ESKD.

Kidney Week 2025 may be coming to a close, but the conversation continues. Hear Meg Jardine, MBBS, PhD, Vineeta Kumar, MD, FASN, and Robert A. Montgomery, MD, PhD, explore research trials and developments in transplant nephrology.

Kidney Week 2025 may be coming to a close, but the conversation continues. Hear Meg Jardine, MBBS, PhD, Vineeta Kumar, MD, FASN, and Robert A. Montgomery, MD, PhD, explore research trials and developments in transplant nephrology.

When should dialysis be withheld at the end of life—and who makes that decision? Join host Raphy Rosen with experts Drs. Alvin Moss and Christine Corbett as they explore the ethical, clinical, and emotional challenges the nephrology team face when considering “no” to dialysis. Learn how shared decision-making, time-limited trials, and compassionate communication can help align care with patient values and improve end-of-life outcomes.   Host: Raphy Rosen, MD, FASN, FNKF Panelists: Christine Corbett, DNP, APRN, FNP-BC, CNN-NP, ACHPN, FNKF and Alvin H. Moss, MD, FACP, FAAHPM

Amber S. Podoll, MD, FASN - Stepping Up Kidney Protection in Patients With Lupus Nephritis: When and How?

Amber S. Podoll, MD, FASN - Stepping Up Kidney Protection in Patients With Lupus Nephritis: When and How?

Discover expert insights on kidney stone prevention and management in this podcast episode featuring a physician, dietitian, pharmacist, and patient. Learn about key kidney stone risk factors and explore how dietary adjustments can reduce stone recurrence. Experts discuss fluid intake strategies, medication considerations, surgical indications, and even unconventional questions about roller coasters' impact on stone passage. Tune in for actionable advice, myth-busting discussions, and interprofessional perspectives.   On today's episode we heard from: Melanie Betz, MS, RD, CSR, FNKF, FAND is a nationally recognized renal dietitian and the Founder & CEO of The Kidney Dietitian. She is a Certified Specialist in Renal Nutrition and a Fellow of both the National Kidney Foundation and the Academy of Nutrition & Dietetics. Melanie has published extensively on kidney stone prevention and nutrition, and has presented at numerous state, national, and international conferences on the topic. Through her clinical work, research, and educational outreach, she is dedicated to helping patients and professionals understand the critical role of diet in kidney health. Mark Garofoli, PharmD, MBA, BCGP, CPE, CTTS is a Clinical Associate Professor at West Virginia University School of Pharmacy and a Clinical Pain & Addiction Pharmacist. With expertise in pain management, substance use disorders, and geriatric care, he brings both clinical and personal perspectives to kidney stone discussions. Mark has shared his experience through the Pain Pod podcast, PAINWeek presentations, and a published article detailing his own kidney stone journey. Mary Raines, CRA is a retired clinical research associate with more than 30 years of experience in medical research. After learning she needed a kidney transplant, she dedicated herself to advocacy and now serves as a Patient Advocate with the National Kidney Foundation and other kidney health organizations. Mary brings both professional expertise and personal experience to her work, amplifying the voices and needs of people living with kidney disease. Andrew Rule, MD, MSc is a Professor of Medicine and Consultant Nephrologist at the Mayo Clinic in Rochester, Minnesota. He divides his time between clinical care, research, and education, with a particular focus on kidney stone disease and its link to chronic kidney disease. Dr. Rule has published extensively on the epidemiology of kidney stones and provides specialized care in the Mayo Clinic's nephrology stone clinic. Bryan Tucker, DO, MS, FASN is an Assistant Professor of Medicine in Nephrology at Baylor College of Medicine, where he serves as a clinician educator teaching medical students, residents, and fellows while caring for patients in both inpatient and outpatient settings. He holds a master's degree in nutrition from Columbia University and completed his nephrology fellowship at Yale. A Fellow of the American Society of Nephrology, Dr. Tucker has authored numerous peer-reviewed publications and book chapters and is an active contributor to The Kidney Commute podcast.   Additional Resources: Kidney Stone Information Earn CME Credit Here Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.  

Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is the fastest-growing etiology of hepatocellular carcinoma (HCC). This work identifies novel gene and lipid associations in human MASLD-driven HCC that may be exploited for therapeutic benefit. Methods: Human HCC tumor (n=8) and adjacent non-tumor samples (n=8) were obtained from the Biospecimen Procurement and Translational Pathology Shared Resource Facility at the University of Kentucky Markey Cancer Center. All patients met cardiometabolic MASLD criteria and were negative for viral hepatitis. Hematoxylin and eosin (H&E) staining was used for pathological determination of tumor and adjacent nontumor tissue. Lipids were extracted using a methyl-tert-butyl ether extraction method and subjected to lipidomics by the West Coast Metabolomics Center. RNA was isolated and used for bulk sequencing. Data were analyzed using paired nonparametric analyses via a Wilcoxon or Mann-Whitney test, as appropriate. Results: Histological analysis by H&E showed significant lipid vacuole accumulation in HCC tumors relative to nontumor tissue. Lipidomic analysis revealed significant increases in long-chain nonesterified monounsaturated fatty acids (MUFAs; C16:1, C18:1, C20:1) and MUFA-enriched phospholipids (PC30:1, PC32:1, PE32:1, and PC36:1) in tumors relative to nontumor tissue. No significant differences were observed in nonesterified polyunsaturated fatty acids (PUFAs; C18:2, C20:4, and C22:6), PUFA-enriched phospholipids (C36:4, C38:4, C38:6, C40:6), or in fatty acid esters of hydroxy fatty acids (FAHFAs; C38:2, C38:4, C38:6). However, both MUFA- (C14:1, C18:1) and PUFA-enriched acylcarnitines (C18:2, C18:3) were collectively reduced in human tumors. Differential analysis of RNA sequencing revealed fatty acid oxidation genes (CPT1A, CPT2, ACADL, ACADM, ACADS, HADHA) were significantly reduced in tumor versus nontumor tissue. Further, genes involved in de novo lipogenesis were largely dysregulated (e.g. no differences in SREBF1 or FASN; increases in ACLY, ACACA, and SCD1; decreases in ACSL1) in tumor versus nontumor tissue. Conclusions: These results suggest human HCC tumors exhibit a reduced capacity to undergo mitochondrial β-oxidation resulting in accumulation of free and esterified MUFAs with concomitant reductions in MUFA-carnitines. Current studies are underway to determine the mechanisms by which impairment of hepatic MUFA catabolism via FAO promotes the development of HCC in mice.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Daniel W. Coyne, MD, and Morgan B. Schoer, MD, about their editorial "Parathyroidectomy for Treatment of Hyperparathyroidism in CKD" from nephSAP Volume 24, Number 3.

Alice Sheridan, MD, FASN, and Martina McGrath, MD, FASN, speak with guest editors Daniel W. Coyne, MD, and Morgan B. Schoer, MD, about their editorial "Parathyroidectomy for Treatment of Hyperparathyroidism in CKD" from nephSAP Volume 24, Number 3.

Andrew J. Cohen, MD, FASN, leads the discussion on McCarthyism and the consequences that doctors leading the field of nephrology faced for their political ties and activism. Guests: Merlin Chowkwanyun, PhD, MPH, Kevin Lemley, MD, PhD, and Leon Fine, MD.

Andrew J. Cohen, MD, FASN, leads the discussion on McCarthyism and the consequences that doctors leading the field of nephrology faced for their political ties and activism. Guests: Merlin Chowkwanyun, PhD, MPH, Kevin Lemley, MD, PhD, and Leon Fine, MD.

Send us a textThis conversation is the fourth and final segment of SurfingMASH's April discussion of drug development in memory of Stephen A. Harrison. In addition to co-hosts Jörn Schattenberg, Louise Campbell and Roger Green, panelists include hepatologist and key opinion leader Sven Francque. The discussion focuses on PPARs, genetic medicines, and other emerging drug classes while considering the idea that drug therapies can have an impact on the liver independent of their effect on fibrosis regression. It begins with Sven  discussing his experience as a lead investigator in clinical trials for the pan-PPAR agonist lanifibranor, whose Phase 3 trial is now fully recruited. Sven states that in addition to fibrosis regression, lanifibranor is likely to exhibit other pleiotropic effects, and notes that vascular changes start early in the fibrotic progression process. After Sven elaborates on these effects, Louise asks about the SCD-1 agent Aramchol. This leads to a discussion about the idea that over time, therapy will probably come to incorporate two separate modes of action, with one to treat the metabolic dysfunction and the other to treat specific effects in the liver or, as Jörn puts it, "combining weight-neutral and weight-reducing drugs." This evolves into a discussion of what Louise terms "personal-centric" medicine, or what patient advocate Mike Betel has previously described on SurfingMASH as "tailored medicine."The rest of the conversation predominantly lists other classes of drugs, "safe" mitochondrial uncouplers, genetic medicines, and others. Roger inquires about the FASN inhibitors, which are entering Phase 3 clinical trials. Jörn says that the data appears positive and unique. That said, he and Sven agree we need more data.Louise sounds the closing note for this roundtable by discussing our co-founder, Stephen Harrison, and the energy and enthusiasm he brought to the entire drug development process. The group agrees that Stephen's impact continues to be felt through the MASLD community, even as he is missed by us all.

Robert Mark Black, MD, and Joel M. Topf, MD, join host Andrew J. Cohen, MD, FASN, in exploring the genesis of Dr. Burton "Bud" Rose's online medical resource—UpToDate—and its lasting impact.

Robert Mark Black, MD, and Joel M. Topf, MD, join host Andrew J. Cohen, MD, FASN, in exploring the genesis of Dr. Burton "Bud" Rose's online medical resource—UpToDate—and its lasting impact.

#ThisMorning on #BRN #Lifestyle  #2089 |  A #Diet High In #Fruits and #Vegetables May #Reduce Your #Heart and #Kidney #Disease #Risk | Donald E. Wesson, MD, MBA, FASN, Texas A&M College of Medicine  | #Tunein: broadcastretirementnetwork.com #Aging, #Finance, #Lifestyle, #Privacy, #Retirement, #Wellness and #More - #everyday

In celebration of Donate Life month, we are sharing a special crossover episode from NKF's Life as a Nephrology Professional podcast. Tune in and hear from three living kidney donors as they discuss the power of living donation and kidney advocacy. Host: Anna Gaddy, MD, FASN, FNKF Guests: Lauren Drew, JD, Beth Burbridge   Additional Resources: Becoming a Living Donor NKF Advocacy   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

Mark Houston welcomes David Kovaleski, M.D., FASN, Critical Care Doctor at Rapid City Hospital, and a true Renaissance man. Dr. Kovaleski recounts his journey to becoming an ICU Physician, relates the challenges of Critical Care and touches on the delicate nature of end-of-life discussions. Beyond the ICU, Dr. Kovaleski, a passionate painter and photographer, credits creativity with helping him navigate the intense nature of Critical Care. He shares his Western-themed artwork and his upcoming portrait series, which features medical professionals.To learn more about Dr. Kovaleski's artwork, visit www.kovaleskiphoto.com Hosted on Acast. See acast.com/privacy for more information.

Der FCB auf Meisterkurs - werden die Basler jetzt wieder «arrogant» (Carlos Varela)? Und seit wann ist Xherdan Shaqiri eigentlich Fasnächtler? Ausserdem: Fahren die Yakins den FC Schaffhausen an die Wand, und kehrt beim FCZ je wieder Ruhe ein? «Sykora Gisler», der Fussball-Podcast von SRF 3-Moderator Tom Gisler und «ZWÖLF»-Chefredaktor Mämä Sykora bietet unterhaltende Gespräche mit Haltung, Herz und einer guten Prise Humor. Zu den beiden Enthusiasten stösst jeweils ein prominenter Gast – der das Duo mit scharfer Zunge und genauso viel Fussballherz ergänzt.

Cannabis or marijuana is becoming increasingly more popular in the United States for recreational and medical use. What is cannabis? Are there benefits to using it? Is it ok for someone with kidney disease or dialysis to use it? Learn all this and more in today's episode. Joshua Rein, DO, FASN, is a board-certified nephrologist, kidney physiologist, and certified hypertension specialist. He is an Assistant Professor in the Barbara T. Murphy Division of Nephrology in the Department of Medicine at the Icahn School of Medicine at Mount Sinai in NYC and a Staff Physician at the James J. Peters, Veterans Affairs Medical Center. He received his medical degree from the New York College of Osteopathic Medicine, completed internal medicine at Mount Sinai Beth Israel, and completed clinical and research nephrology fellowships at Mount Sinai Hospital. Dr. Rein is interested in the effects of cannabis and cannabinoids on kidney health and disease given their widespread growing popularity despite an uncertain impact on health. Dr. Rein's research, funded by a Veterans Affairs Career Development Award, utilizes preclinical animal models to characterize the kidney endocannabinoid system and examine the physiological impact of cannabinoids on the regulation of fluid and electrolyte balance by the kidney. His clinical research focuses on the risks, benefits, and clinical significance of cannabis consumption among people with kidney disease and those at risk for developing kidney disease.   Additional Resources: Nephrologist's Guide to Cannabis Cannabis Usage Study AJKD Blog   Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.

This episode is brought to you by BiOptimizers, Levels, and Air Doctor. What if there was one key nutrient that could boost your health, increase longevity, reduce chronic inflammation, and lower your risk of Alzheimer's? You've probably heard of it: omega-3! But here's the surprising part—over 90% of the population has suboptimal omega-3 levels. Today on The Dhru Purohit Show, we're revisiting one of our favorite episodes with Dr. Bill Harris, a world-renowned researcher, to dive into decades of research on omega-3s and their powerful impact on health. Dr. Harris explains the correlation between optimal omega-3 levels and longer life spans, reduced rates of depression, anxiety, and Alzheimer's, as well as their role in lowering chronic inflammation. As one of the most researched nutrients—and among the top three that can drastically improve health—omega-3s are essential. In this episode, Dr. Harris shares insights on choosing quality fish and supplements, understanding optimal omega-3 levels, and testing your levels through the OmegaQuant Institute. If you're looking for inspiration to prioritize omega-3s in your diet, this conversation is a must-listen! William S. Harris, PhD, FASN, has been a leading researcher in the field of omega-3 fatty acids for 40 years. He has authored over 300 scientific papers on fatty acids and health, served on the faculty of three medical schools, and received five NIH grants to study omega-3s. Dr. Harris co-authored three American Heart Association (AHA) statements on fatty acids and heart health. As the co-inventor of the Omega-3 Index and other omega-3 blood tests, as well as the founder of OmegaQuant Analytics, Dr. Harris has been ranked among the top 2% of scientists worldwide for the impact of his research. In this episode, Dhru and Dr. Harris dive into: Higher levels of omega-3's lead to a longer life (00:00:35) Omega-3s are in the top three nutrients that can improve our health (3:00) Mindblowing research on smokers and the protective nature of omega-3s (5:25) The link between low omega-3s, depression, mood, and anxiety (16:12)  High levels of omega-3s and their correlation to reducing the risk for dementia and Alzheimer's (20:21) The research behind omega-3's and reducing chronic inflammation (28:32)  The average omega-3 levels versus optimal levels (30:45)  What has led to omega-3 deficiencies and the rise in ultra-processed food consumption (31:10)   Reducing triglyceride levels with fish oil and the impact on our cells (32:43)  What are EPA, DHA, and ALA, and the sources of each (36:35) How much fish consumption is optimal, and what kind (44:40) Testing your levels via the Omega-3 index and optimal ranges (49:40) Choosing the right fish oil and general dosage (59:10)  Testing pregnant women and children (1:22:40)  Why the omega-3s aren't being tested for and prescribed by every doctor (1:26:00)  Also mentioned in this episode: Testing via OmegaQuant Fatty Acid Research Insitute  For more on Dr. Harris, follow OmegaQuant via Instagram, Twitter, and Facebook.  This episode is brought to you by BiOptimizers, Levels, and Air Doctor. Go to bioptimizers.com/dhru now and enter promo code DHRU10 to get 10% off any order and up to 2 travel-size bottles of Magnesium Breakthrough for a limited time. Right now, Levels is offering my listeners an additional 2 FREE months of the Levels annual Membership when you use my link, levels.link/DHRU. Make moves on your metabolic health with Levels today.  AirDoctor is offering my community $300 off. Just go to dhrupurohit.com/filter/ to clean up your home's air and feel better today.  Learn more about your ad choices. Visit megaphone.fm/adchoices